PURMX Therapeutics develops RNA-based nucleic acid drugs, specifically targeting malignant pleural mesothelioma through its proprietary functional RNA screening platform. The company aims to provide effective therapies for patients with intractable cancers by utilizing small ribonucleic acids to eliminate cancer cells.
Funding
$6.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Malignant pleural mesothelioma, an intractable cancer, lacks effective therapies, leaving patients with limited treatment options and poor prognoses. Current treatments often fail to eliminate cancer cells completely, resulting in disease progression and reduced quality of life.
Solution
PURMX Therapeutics is developing RNA-based nucleic acid drugs that specifically target and eliminate cancer cells in malignant pleural mesothelioma. The company utilizes a proprietary functional RNA screening platform to identify and optimize small ribonucleic acids with the potential to completely kill cancer cells. Their lead product, MIRX002, is based on the novel concept of an "Aging switch" and is currently undergoing a first-in-human investigator-initiated clinical trial. PURMX Therapeutics aims to create innovative anti-cancer drugs that offer a complete cure, not just prolonged life, for patients suffering from intractable diseases.
Target Audience
The primary target audience includes patients suffering from malignant pleural mesothelioma and other intractable cancers, as well as oncologists and medical professionals seeking more effective treatment options.
Features
- Proprietary functional RNA screening platform for identifying effective nucleic acid drug candidates.
- MIRX002: A first-in-class drug based on the "Aging switch" concept, designed to completely kill cancer cells.
- Focus on developing nucleic acid drugs optimized for treating diseases with high unmet needs.
- Pipeline assets showing efficacy in various cancer types beyond malignant pleural mesothelioma.
- Collaborative approach with companies possessing innovative technologies such as DDS (Drug Delivery Systems) to enhance drug delivery.